These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38363175)

  • 1. Diagnostic value of CSF chromogranin A to discriminate between Alzheimer's disease and dementia with Lewy bodies.
    Bousiges O; Lavaux T; Demuynck C; Schaeffer-Agalède C; Philippi N; Muller C; Cretin B; Blanc F
    Neuropathol Appl Neurobiol; 2024 Feb; 50(1):e12961. PubMed ID: 38363175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer's disease at the prodromal stage.
    Bousiges O; Bombois S; Schraen S; Wallon D; Quillard MM; Gabelle A; Lehmann S; Paquet C; Amar-Bouaziz E; Magnin E; Miguet-Alfonsi C; Delbeuck X; Lavaux T; Anthony P; Philippi N; Blanc F;
    J Neurol Neurosurg Psychiatry; 2018 May; 89(5):467-475. PubMed ID: 29321140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.
    Bousiges O; Cretin B; Lavaux T; Philippi N; Jung B; Hezard S; Heitz C; Demuynck C; Gabel A; Martin-Hunyadi C; Blanc F
    J Alzheimers Dis; 2016; 51(4):1069-83. PubMed ID: 26923009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer's disease and dementia with Lewy bodies from the prodromal stage.
    Bousiges O; Philippi N; Lavaux T; Perret-Liaudet A; Lachmann I; Schaeffer-Agalède C; Anthony P; Botzung A; Rauch L; Jung B; de Sousa PL; Demuynck C; Martin-Hunyadi C; Cretin B; Blanc F
    Alzheimers Res Ther; 2020 Sep; 12(1):120. PubMed ID: 32993772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.
    van Steenoven I; Aarsland D; Weintraub D; Londos E; Blanc F; van der Flier WM; Teunissen CE; Mollenhauer B; Fladby T; Kramberger MG; Bonanni L; Lemstra AW;
    J Alzheimers Dis; 2016 Aug; 54(1):287-95. PubMed ID: 27567832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF amyloid β38 as a novel diagnostic marker for dementia with Lewy bodies.
    Mulugeta E; Londos E; Ballard C; Alves G; Zetterberg H; Blennow K; Skogseth R; Minthon L; Aarsland D
    J Neurol Neurosurg Psychiatry; 2011 Feb; 82(2):160-4. PubMed ID: 21047883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.
    Luo X; Hou L; Shi H; Zhong X; Zhang Y; Zheng D; Tan Y; Hu G; Mu N; Chan J; Chen X; Fang Y; Wu F; He H; Ning Y
    J Neurochem; 2013 Dec; 127(5):681-90. PubMed ID: 23800322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies.
    Vrillon A; Bousiges O; Götze K; Demuynck C; Muller C; Ravier A; Schorr B; Philippi N; Hourregue C; Cognat E; Dumurgier J; Lilamand M; Cretin B; Blanc F; Paquet C
    Alzheimers Res Ther; 2024 Jul; 16(1):146. PubMed ID: 38961441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
    Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
    J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study.
    Morimoto S; Takao M; Hatsuta H; Nishina Y; Komiya T; Sengoku R; Nakano Y; Uchino A; Sumikura H; Saito Y; Kanemaru K; Murayama S
    PLoS One; 2017; 12(2):e0171524. PubMed ID: 28166276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia.
    Spies PE; Slats D; Sjögren JM; Kremer BP; Verhey FR; Rikkert MG; Verbeek MM
    Curr Alzheimer Res; 2010 Aug; 7(5):470-6. PubMed ID: 20043812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies.
    van Steenoven I; van der Flier WM; Scheltens P; Teunissen CE; Lemstra AW
    Alzheimers Res Ther; 2019 Oct; 11(1):83. PubMed ID: 31601267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations of Neuropsychiatric Features with Cerebrospinal Fluid Biomarkers of Amyloidogenesis and Neurodegeneration in Dementia with Lewy Bodies Compared with Alzheimer's Disease and Cognitively Healthy People.
    de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
    J Alzheimers Dis; 2021; 81(3):1295-1309. PubMed ID: 33935098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease.
    Morenas-Rodríguez E; Alcolea D; Suárez-Calvet M; Muñoz-Llahuna L; Vilaplana E; Sala I; Subirana A; Querol-Vilaseca M; Carmona-Iragui M; Illán-Gala I; Ribosa-Nogué R; Blesa R; Haass C; Fortea J; Lleó A
    Sci Rep; 2019 May; 9(1):7803. PubMed ID: 31127154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
    de Oliveira FF; Miraldo MC; de Castro-Neto EF; de Almeida SS; Matas SLA; Bertolucci PHF; Naffah-Mazzacoratti MDG
    Aging Clin Exp Res; 2023 Aug; 35(8):1741-1752. PubMed ID: 37264166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
    Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
    J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.
    Vanderstichele H; De Vreese K; Blennow K; Andreasen N; Sindic C; Ivanoiu A; Hampel H; Bürger K; Parnetti L; Lanari A; Padovani A; DiLuca M; Bläser M; Olsson AO; Pottel H; Hulstaert F; Vanmechelen E
    Clin Chem Lab Med; 2006; 44(12):1472-80. PubMed ID: 17163825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.